These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25266815)

  • 1. Utilities for treatment-related adverse events in type 2 diabetes.
    Shingler S; Fordham B; Evans M; Schroeder M; Thompson G; Dewilde S; Lloyd AJ
    J Med Econ; 2015 Jan; 18(1):45-55. PubMed ID: 25266815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study.
    Amos TB; Montejano L; Juneau P; Bolge SC
    J Med Econ; 2017 Mar; 20(3):303-313. PubMed ID: 27826987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom.
    Levy AR; Christensen TL; Johnson JA
    Health Qual Life Outcomes; 2008 Sep; 6():73. PubMed ID: 18823555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey.
    Harris S; Mamdani M; Galbo-Jørgensen CB; Bøgelund M; Gundgaard J; Groleau D
    Can J Diabetes; 2014 Feb; 38(1):45-52. PubMed ID: 24485213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health state utilities associated with attributes of treatments for hepatitis C.
    Matza LS; Sapra SJ; Dillon JF; Kalsekar A; Davies EW; Devine MK; Jordan JB; Landrian AS; Feeny DH
    Eur J Health Econ; 2015 Dec; 16(9):1005-18. PubMed ID: 25481796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes.
    Florez H; Luo J; Castillo-Florez S; Mitsi G; Hanna J; Tamariz L; Palacio A; Nagendran S; Hagan M
    Postgrad Med; 2010 Mar; 122(2):112-20. PubMed ID: 20203462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus.
    Brunton SA
    Postgrad Med; 2012 Jul; 124(4):74-83. PubMed ID: 22913896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Burden and Costs Associated with Urinary Tract Infections in Type 2 Diabetes Mellitus Patients: An Analysis Based on a Large Sample of 456,586 German Patients.
    Wilke T; Böttger B; Berg B; Groth A; Botteman M; Yu S; Fuchs A; Maywald U
    Nephron; 2016; 132(3):215-26. PubMed ID: 26930608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S; Deng J; Shi L; Mu Y; Dong H
    J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications.
    Yfantopoulos J; Chantzaras A
    Eur J Health Econ; 2020 Jul; 21(5):729-743. PubMed ID: 32128637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.
    McEwan P; Baker-Knight J; Ásbjörnsdóttir B; Yi Y; Fox A; Wyn R
    Eur J Health Econ; 2023 Mar; 24(2):187-196. PubMed ID: 35526173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilities and disutilities for type 2 diabetes treatment-related attributes.
    Matza LS; Boye KS; Yurgin N; Brewster-Jordan J; Mannix S; Shorr JM; Barber BL
    Qual Life Res; 2007 Sep; 16(7):1251-65. PubMed ID: 17638121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstrating the burden of hypoglycemia on patients' quality of life in diabetes clinical trials: measurement considerations for hypoglycemia.
    Gilet H; Gruenberger JB; Bader G; Viala-Danten M
    Value Health; 2012 Dec; 15(8):1036-41. PubMed ID: 23244805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan.
    Strizek A; Chang CJ; Furnback W; Wang B; Lebrec J; Lew T
    Value Health Reg Issues; 2019 May; 18():84-90. PubMed ID: 30776767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.
    Boye KS; Matza LS; Walter KN; Van Brunt K; Palsgrove AC; Tynan A
    Eur J Health Econ; 2011 Jun; 12(3):219-30. PubMed ID: 20224930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
    Thompson AM; Linnebur SA; Vande Griend JP; Saseen JJ
    Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.